Novartis plots 'next frontier' of MS treatment — and it could spell a buyout for a small Swiss player
A couple of months after getting its self-administered multiple sclerosis drug Kesimpta cleared by EU regulators, Novartis has found what it believes is “the next frontier” of MS treatment at a University of Zurich spinout — and it’s already laying the groundwork for a buyout.
Novartis struck a deal to develop Cellerys’ cell therapy CLS12311, which is designed to induce antigen-specific immune tolerance in MS patients, the pharma said on Tuesday. The drugmakers have been in talks for several years, according to a Novartis spokesperson, and upon completion of a Phase II trial in “coming years,” the pharma will have a chance to acquire Cellerys.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.